A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 2 Dose Regimens of Orally Administered SENS-111 (100 mg and 200 mg) Given During 4 Days in Patients Suffering From Acute Unilateral Vestibulopathy

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 2 Dose Regimens of Orally Administered SENS-111 (100 mg and 200 mg) Given During 4 Days in Patients Suffering From Acute Unilateral Vestibulopathy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs SENS 111 (Primary)
  • Indications Vertigo
  • Focus Therapeutic Use
  • Acronyms SENSORION
  • Sponsors Sensorion
  • Most Recent Events

    • 29 Jun 2017 Planned End Date changed from 1 Apr 2019 to 1 Dec 2018.
    • 29 Jun 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Dec 2018.
    • 22 Jun 2017 Planned primary completion date changed from 1 May 2018 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top